300 related articles for article (PubMed ID: 27814963)
21. Prevention of Cervix Cancer in India.
Mishra GA; Pimple SA; Shastri SS
Oncology; 2016; 91 Suppl 1():1-7. PubMed ID: 27463969
[TBL] [Abstract][Full Text] [Related]
22. Single-Dose Human Papillomavirus Vaccination in Low- and Middle-Income Countries-Time for Implementation?
Gallant D; Tummers P; Weyers S; Merckx M
J Pediatr Adolesc Gynecol; 2021 Oct; 34(5):586-590. PubMed ID: 34144176
[TBL] [Abstract][Full Text] [Related]
23. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
24. Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models.
Jit M; Demarteau N; Elbasha E; Ginsberg G; Kim J; Praditsitthikorn N; Sinanovic E; Hutubessy R
BMC Med; 2011 May; 9():54. PubMed ID: 21569406
[TBL] [Abstract][Full Text] [Related]
25. The investment case for cervical cancer elimination.
Tsu VD; Ginsburg O
Int J Gynaecol Obstet; 2017 Jul; 138 Suppl 1():69-73. PubMed ID: 28691328
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of interventions for improving timely diagnosis of breast and cervical cancers in low-income and middle-income countries: a systematic review.
Nnaji CA; Kuodi P; Walter FM; Moodley J
BMJ Open; 2022 Apr; 12(4):e054501. PubMed ID: 35470184
[TBL] [Abstract][Full Text] [Related]
27. National implementation of HPV vaccination programs in low-resource countries: Lessons, challenges, and future prospects.
Tsu VD; LaMontagne DS; Atuhebwe P; Bloem PN; Ndiaye C
Prev Med; 2021 Mar; 144():106335. PubMed ID: 33678232
[TBL] [Abstract][Full Text] [Related]
28. A Framework for Cervical Cancer Elimination in Low-and-Middle-Income Countries: A Scoping Review and Roadmap for Interventions and Research Priorities.
Shin MB; Liu G; Mugo N; Garcia PJ; Rao DW; Bayer CJ; Eckert LO; Pinder LF; Wasserheit JN; Barnabas RV
Front Public Health; 2021; 9():670032. PubMed ID: 34277540
[TBL] [Abstract][Full Text] [Related]
29. Prevention of cervical cancer in HIV-seropositive women from developing countries through cervical cancer screening: a systematic review.
Mapanga W; Girdler-Brown B; Feresu SA; Chipato T; Singh E
Syst Rev; 2018 Nov; 7(1):198. PubMed ID: 30447695
[TBL] [Abstract][Full Text] [Related]
30. Underutilization of cervical cancer prevention services in low and middle income countries: a review of contributing factors.
Chidyaonga-Maseko F; Chirwa ML; Muula AS
Pan Afr Med J; 2015; 21():231. PubMed ID: 26523173
[TBL] [Abstract][Full Text] [Related]
31. Cervical cancer prevention in Morocco: a model-based cost-effectiveness analysis.
Messoudi W; Elmahi T; Nejjari C; Tachfouti N; Zidouh A; Saadani G; Moriña D; Diaz M
J Med Econ; 2019 Nov; 22(11):1153-1159. PubMed ID: 31135231
[No Abstract] [Full Text] [Related]
32. Why Consider Self-Sampling for Cervical Cancer Screening in Low- and Middle-Income Countries?
Fokom Defo V; Fokom Domgue J
AMA J Ethics; 2020 Feb; 22(2):E116-125. PubMed ID: 32048582
[TBL] [Abstract][Full Text] [Related]
33. Benefits of catch-up in vaccination against human papillomavirus in medium- and low-income countries.
Baussano I; Lazzarato F; Ronco G; Dillner J; Franceschi S
Int J Cancer; 2013 Oct; 133(8):1876-81. PubMed ID: 23564420
[TBL] [Abstract][Full Text] [Related]
34. Assessment of the Broader Economic Consequences of HPV Prevention from a Government-Perspective: A Fiscal Analytic Approach.
Setiawan D; Kotsopoulos N; Wilschut JC; Postma MJ; Connolly MP
PLoS One; 2016; 11(8):e0160707. PubMed ID: 27490258
[TBL] [Abstract][Full Text] [Related]
35. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China.
Levin CE; Sharma M; Olson Z; Verguet S; Shi JF; Wang SM; Qiao YL; Jamison DT; Kim JJ
Vaccine; 2015 Jun; 33(24):2830-41. PubMed ID: 25770785
[TBL] [Abstract][Full Text] [Related]
36. What works for human papillomavirus vaccine introduction in low and middle-income countries?
Howard N; Gallagher KE; Mounier-Jack S; Burchett HED; Kabakama S; LaMontagne DS; Watson-Jones D
Papillomavirus Res; 2017 Dec; 4():22-25. PubMed ID: 29179865
[TBL] [Abstract][Full Text] [Related]
37. A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.
Guerrero AM; Genuino AJ; Santillan M; Praditsitthikorn N; Chantarastapornchit V; Teerawattananon Y; Alejandria M; Toral JA
BMC Public Health; 2015 Jul; 15():730. PubMed ID: 26223975
[TBL] [Abstract][Full Text] [Related]
38. Treatment approaches for women with positive cervical screening results in low-and middle-income countries.
Wentzensen N; Chirenje ZM; Prendiville W
Prev Med; 2021 Mar; 144():106439. PubMed ID: 33678236
[TBL] [Abstract][Full Text] [Related]
39. Integrating human papillomavirus vaccination in cervical cancer control programmes.
Franco EL; Coutlée F; Ferenczy A
Public Health Genomics; 2009; 12(5-6):352-61. PubMed ID: 19684447
[TBL] [Abstract][Full Text] [Related]
40. Human papillomavirus: science and technologies for the elimination of cervical cancer.
Bosch FX
Expert Opin Pharmacother; 2011 Oct; 12(14):2189-204. PubMed ID: 21756205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
